Acadian Asset Management
TSHA icon

Acadian Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Acadian Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,477
Closed -$75K – 1908
2024
Q1 		$75K Sell
26,477
-433,589
-94% -$904K ﹤0.01% 1330
2023
Q4 		$813K Buy
+460,066
New +$917K ﹤0.01% 918
2023
Q3 		– Sell
-70,798
Closed -$46K – 1848
2023
Q2 		$46K Sell
70,798
-334,503
-83% -$242K ﹤0.01% 1544
2023
Q1 		$321K Buy
405,301
+143,450
+55% +$185K ﹤0.01% 1154
2022
Q4 		$590K Buy
261,851
+208,404
+390% +$422K ﹤0.01% 989
2022
Q3 		$102K Hold
53,447
– – ﹤0.01% 1360
2022
Q2 		$199K Buy
+53,447
New +$212K ﹤0.01% 1198

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management's TSHA Position: Q2 2024 in Review

Acadian Asset Management sold out of Taysha Gene Therapies (TSHA) in Q2 2024, closing a stake of 26,477 shares — an estimated $75K sold.

Acadian Asset Management first reported a position in TSHA in Q2 2022 and held it in 7 quarters. The position peaked at $813K in Q4 2023. 107 funds tracked by Wall St. Rank hold TSHA as of Q2 2024.

  • Acadian Asset Management reported no remaining Taysha Gene Therapies position as of Q2 2024 after selling out during the quarter.
  • Acadian Asset Management sold 26,477 Taysha Gene Therapies shares in Q2 2024, an estimated $75K.
  • Acadian Asset Management first reported a position in Taysha Gene Therapies in Q2 2022 and held it in 7 quarters.
  • Acadian Asset Management's Taysha Gene Therapies position peaked at $813K in Q4 2023.
  • 107 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.